You have read all your free articles, to continue reading subscribe to read the rest of this content.
Lytix Biopharma has announced promising data results from a phase I study of its lead candidate LTX-315. The findings were published in Clinical Cancer Research. “A major and persistent challenge in today’s cancer treatment is lack of tumor infiltrating T cells in the majority of cancer paAlready a subscriber Login…
Aqilion has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has approved the company’s Phase 1 clinical trial with its drug candidate AQ280. Aqilion applied to conduct a Phase I safety study in 64 healthy volunteers with the drug candidate AQ280 within thAlready a subscriber…
Nanoform has announced positive interim results from its clinical study. The faster absorption data implies that small particles can indeed be powerful, states the company in its press release. Phase I trial Nanoform has received interim study results related to its Phase 1, Single-Centre, PartAlready a subscriber Login You have…
BerGenBio has announced that bemcentinib has been selected as the first potential treatment to be fast-tracked in a new UK national multi-centre randomized Phase II clinical trial initiative. The ACcelerating COVID-19 Research & Development platform (ACCORD) study is being funded by the DeparAlready a subscriber Login You have read all…
